Ibrutnib in Older Patients With Mantle Cell Lymphoma

Video

Brad S. Kahl, MD, professor in the department of medicine at Washington School of Medicine at Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in older patients with mantle cell lymphoma. This agent is currently being investigated in the frontline setting for patients not eligible for stem cell transplant.

Brad S. Kahl, MD, professor in the department of medicine at Washington School of Medicine at Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in older patients with mantle cell lymphoma. This agent is currently being investigated in the frontline setting for patients not eligible for stem cell transplant.

SHINE is a larger trial that is fully enrolled, but the readout is not available yet. Patients in this trial were randomized to receive either bendamustine or rituximab (Rituxan), or a combination of bendamustine/rituximab plus ibrutinib. Ibrutinib was also continued as a post-remission therapy, according to Kahl.

Recent Videos
Related Content
Brexu-cel Achieves Strong CNS and Systemic Responses in Adult B-ALL Patients

Brexu-cel Achieves Strong CNS and Systemic Responses in Adult B-ALL Patients

Jordyn Sava
November 22nd 2024
Article

Ibrahim N. Muhsen, MD, evaluated the efficacy of brexu-cel in adult patients with central nervous system involvement in relapsed/refractory B-cell acute lymphoblastic leukemia.

Read More

FGFR-Altered NMIBC Treatment Advances With TAR-210 Findings

FGFR-Altered NMIBC Treatment Advances With TAR-210 Findings

Jordyn Sava
November 21st 2024
Article

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.

Read More

Improving Outcomes Using Ribociclib in High-Risk Node-Negative Breast Cancer

Improving Outcomes Using Ribociclib in High-Risk Node-Negative Breast Cancer

Jordyn Sava
November 21st 2024
Article

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node involvement who were enrolled in the phase 3 NATALEE trial.

Read More

Optimizing Treatment in Myeloma With Biweekly Dosing of Talquetamab

Optimizing Treatment in Myeloma With Biweekly Dosing of Talquetamab

Jordyn Sava
November 20th 2024
Article

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma.

Read More

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Jonah Feldman
November 15th 2024
Article

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

Read More

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Morgan Bayer
November 14th 2024
Article

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

Read More